The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus A model of medicine-based evidence

[1]  Standards of Medical Care for Patients With Diabetes Mellitus , 1998, Diabetes Care.

[2]  G. Dinant,et al.  Medicine based evidence, a prerequisite for evidence based medicine , 1997, BMJ.

[3]  X. Pi-Sunyer,et al.  Acarbose in the Treatment of Type I Diabetes , 1997, Diabetes Care.

[4]  D. V. van Thiel,et al.  A Comparison of Acarbose Versus Metformin as an Adjuvant Therapy in Sulfonylurea-Treated NIDDM Patients , 1996, Diabetes Care.

[5]  J. A. Hunt,et al.  A Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of Acarbose for the Treatment of Patients With Insulin-Requiring Type II Diabetes , 1995, Diabetes Care.

[6]  J. McGill,et al.  Reduction of Glycosylated Hemoglobin and Postprandial Hyperglycemia by Acarbose in Patients With NIDDM: A placebo-controlled dose-comparison study , 1995, Diabetes Care.

[7]  G. Bray,et al.  Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. , 1995, The American journal of medicine.

[8]  R. Coniff,et al.  Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. , 1994, Archives of internal medicine.

[9]  D. McTavish,et al.  Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus. , 1993, Drugs.

[10]  J. Proietto,et al.  Low-Dose Acarbose Improves Glycemic Control in NIDDM Patients Without Changes in Insulin Sensitivity , 1993, Diabetes Care.

[11]  B Leese,et al.  The costs of diabetes and its complications. , 1992, Social science & medicine.

[12]  G. Pagano,et al.  Double‐blind Crossover Study of Acarbose in Type 1 Diabetic Patients , 1991, Diabetic Medicine.

[13]  M. Hanefeld,et al.  Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone , 1991, Diabetes Care.

[14]  G A Colditz,et al.  The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.

[15]  D L Sackett,et al.  An assessment of clinically useful measures of the consequences of treatment. , 1988, The New England journal of medicine.

[16]  S. Clissold,et al.  Acarbose: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential , 1988 .

[17]  S. Raptis,et al.  Effects of Prolonged (6 Months) α-Glucosidase Inhibition on Blood Glucose Control and Insulin Requirements in Patients with Insulin-Dependent Diabetes Mellitus , 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[18]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[19]  K. Johansen.  Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin. , 1984, Diabete & metabolisme.

[20]  B. Clarke,et al.  Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes , 2004, European Journal of Clinical Pharmacology.

[21]  P. Brunetti,et al.  Efficacy and safety of two different dosages of acarbose in non-insulin dependent diabetic patients treated by diet alone , 1993 .

[22]  L. Monnier,et al.  Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus. , 1988, Diabete & metabolisme.